St. Jude to begin Angstrom ICD implants in Europe this fall, firm says at Piper Jaffray conference.
This article was originally published in The Gray Sheet
Executive Summary
ST. JUDE TO BEGIN IMPLANTING ANGSTROM SERIES OF ICDs IN EUROPE by the end of September, Terry Shepherd, acting chief financial officer, said June 18 at the Piper Jaffray investment conference in Minneapolis. The new line of 44 cc single-chamber implantable cardioverter defibrillators, which were developed by the firm's Ventritex unit, includes the Angstrom II, as well as a more advanced version called the Angstrom MD, Shepherd said. St. Jude plans simultaneous premarket approval application supplement submissions to FDA, the company says.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.